Abstract
We report a case of a 53-year old patient with symptoms of congestive heart failure in whom a restrictive cardiomyopathy and a kappa-chain monoclonal gammopahty were diagnosed. Treatment with eight cycles of Bortezomib, a proteasome inhibitor, resulted in a significant regression of myocardial amyloid deposition and a notable clinical and hemodynamic improvement. Over the last few years, the management of cardiac amyloidosis has taken advantage of many of the advances of the chemotherapeutic regimens, as well as the wider availability of stem cell transplantation. The management of cardiac amyloidosis is also expected to evolve and improve with the better understanding of the specific mechanisms of amyloidogenesis and myocardial deposition. This will probably make certain molecules targeting specific sites in this process, as potentially effective and minimally toxic compared therapy with the currently used ones. In this article, we describe one of the first reported cases of cardiac amyloidosis, successfully treated with Bortezomib. We describe and discuss the mechanisms of action of Bortezomib and provide a detailed review of cardiac amyloidosis, from pathophysiology to diagnosis and treatment.
Call for Papers in Thematic Issues
Advances in Aortic Disease Research and Management
This thematic issue of Current Cardiology Reviews will explore cutting-edge developments in the understanding, diagnosis, and treatment of aortic diseases, with a focus on abdominal aortic aneurysm (AAA) and aortic dissection. Comprising 10-12 articles by leading experts, the issue will cover critical topics such as single-cell RNA sequencing (scRNA-seq) to ...read more
Advances in Managing Cardiogenic Shock and the Value of Percutaneous Mechanical Circulatory Support
Despite the advances in cardiology, the outcomes of patients with cardiogenic shock remain poor. There is an increasing interest and use of mechanical circulatory support for patients with cardiogenic shock. Additionally, the complexity of coronary interventions has increased during the last decade with the potential of treating more high-risk patients ...read more
Artificial Intelligence (AI) in Cardiovascular Disease
Artificial Intelligence (AI) in cardiovascular disease is an emerging interdisciplinary field that integrates advanced technologies to improve patient care. The current AI landscape faces significant challenges, including the complexity of diagnosing and treating these conditions. Recent studies have shown promising results in the use of AI for early detection, diagnosis, ...read more
Chronic Disease Self-Management for Heart Failure – A Mini Review into Performance Gaps
Chronic disease self-management (CDSM) is a vital component of chronic disease management. There remain several important deficits in this concept. Its benefit are clear, many chronic diseases such as hypertension, diabetes, asthma, rheumatology syndromes have shown benefit in quality of life and quantitative measures of outcomes. Yet, in congestive heart ...read more
Related Books
Blood Oxidant Ties: The Evolving Concepts in Myocardial Injury and Cardiovascular Disease
Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives
Herbal Medicine: Back to the Future
Cardiac Care and COVID-19: Perspectives in Medical Practice
Nanomedicinal Approaches Towards Cardiovascular Disease
Herbal Medicine: Back to the Future
6